| abstract |
Compounds of formula I (see formula I) are provided (R = aryl, cycloalkyl or polyhaloalkyl, R1 = alkyl, alkoxy, polyfluoroalkoxy, hydroxy or trifluoromethanesulfonyloxy, each of R2 and R3, independently, = H, halogen, alkoxy or polyfluoroalkoxy, n is 0, 1 or 2) and its N-oxides or pharmaceutically acceptable salts which are endowed with enhanced selectivity by the adrenergic receptor 20 and a low activity in the reduction of blood pressure. This activity profile makes these compounds useful in the treatment of obstructive syndromes of the lower urinary tract, including benign prostatic hyperplasia (BPH), decreased intraocular pressure, in the treatment of cardiac arrhythmia and erectile and sexual dysfunction, and in the treatment of symptoms in the lower urinary tract (LUTS) and neurogenic lower urinary tract dysfunction (NLUTD). Compounds I per se, pharmaceutical compositions containing compounds 1 and the medical uses of compounds I are claimed. |